• 1
    Young L, Alfieri C, Hennessy K et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989; 321: 10801085.
  • 2
    Yang J, Tao Q, Flinn IW et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 40554063.
  • 3
    Grant D. Intestinal transplantation: 1997 report of the international registry. Intestinal Transplant Registry. Transplantation 1999; 67: 10611064.
  • 4
    Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: Incidence, presentation and response to treatment in lung transplant recipients. Chest 2003; 124: 12421249.
  • 5
    Cherikh WS, Kauffman HM, McBride MA, Maghirang JM, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival and patient survival after primary kidney transplantation. Transplantation 2003; 76: 12891293.
  • 6
    Harris NL, Swerdlow SH, Frizzera G et al. Post-transplant lymphoproliferative disorers. In: JaffeES, HarrisNL, SteinH, VardlmanJW, eds. World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoetic and lymphoid tissues. Cheenra : IARC Press 2001: 264269.
  • 7
    Leblond V, Dhedin N, Mamzer Bruneel MF et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19: 772778.
  • 8
    Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583587.
  • 9
    Mentzer SJ, Fingeroth J, Reilly JJ et al. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol Dis 1998; 24: 114123.
  • 10
    Oertel SH, Anagnostopoulos I, Hummel MW et al. Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Haematol 2002; 118: 11201123.
  • 11
    Oertel SH, Riess H. Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations. Recent Results Cancer Res 2002; 159: 8995.
  • 12
    Garrett TJ, Chadburn A, Barr ML et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1993; 72: 27822785.
  • 13
    Choquet S, Leblond V, Jager U et al. Efficacy of CHOP regimen as first line therapy in Posttransplantation Lymphoproliferative Disorders (PTLD). A retrospective study on 25 cases. Blood 2003; 102: (abstr, suppl 2)
  • 14
    Fischer A, Blanche S, Le Bidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 14511456.
  • 15
    Leblond V, Sutton L, Dorent R et al. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961968.
  • 16
    Benkerrou M, Jais JP, Leblond V et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 1998; 92: 31373147.
  • 17
    Haddad E, Paczesny S, Leblond V et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial. Blood 2001; 97: 15901597.
  • 18
    Milpied N, Vasseur B, Parquet N. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000; 11(Suppl 1): 113116.
  • 19
    Oertel SH, Anagnostopoulos I, Bechstein et al. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: A new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? Transplantation 2000; 69: 430432.
  • 20
    Verschuuren EA, Stevens SJ, Van Imhoff GW et al. Treatment of posttransplant lymphoproliferative disease with rituximab: The remission, the relapse and the complication. Transplantation 2002; 73: 100104.
  • 21
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207214.
  • 22
    Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 19271932.
  • 23
    McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: The single-agent pivotal trial. Semin Oncol 1999; 26: 7987.